Advertisement

Advertisement
Gastroesophageal Cancer

Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer

In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-free survival vs continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric/gastroesophageal junction cancer.

Cardio-oncology

Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology

A recent report highlighted evidence-based recommendations for the prevention, detection, and management of cancer therapy–related cardiovascular toxicity and cardiovascular events in patients with cancer, as well as knowledge gaps. Select considerations are summarized herein.

 

Leukemia

MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML

As reported in the Journal of Clinical Oncology by Russell et al, the NCRI AML18 trial has shown survival benefit with treatment intensification in fit older patients with measurable residual disease (MRD)-positive response after first induction for acute myeloid leukemia (AML).


Advertisement
Head and Neck Cancer

Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin

As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III portion  of the trial was not performed.

 

Lung Cancer

Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC

Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry method for comparing the pharmacokinetic properties of three EGFR tyrosine kinase inhibitors and their major metabolites in mouse models and patients with non–small cell lung cancer (NSCLC), according to a recent study published by Bailleul et al in the National Science Review. The findings could provide a pharmacokinetic basis for the clinical application of aumolertinib and the development of next-generation EGFR TKIs.

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Award Recipients Announced for the 2024 San Antonio Breast Cancer Symposium

The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast cancer research during the 2024 SABCS. 2024 AACR Distinguished Lectureship in Breast Cancer Research ...

Advertisement

Common Bacterial Toxin May Speed Up Colorectal Cancer Metastasis

A bacterial toxin may accelerate the spread of colorectal cancer to other parts of the body, according to a recent study published by He et al in Cell Host & Microbiome. The findings could pave the way for novel tools to detect metastatic colorectal cancer early and determine which patients may ...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Immunotherapy
Lung Cancer

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...

Multiple Myeloma

Will CAR T-Cell Therapy Be the Magic Bullet for My Multiple Myeloma?

Darlene Pruess Intense pain on the right side of my lower rib cage, in 2020, sent me first to my chiropractor for relief and then to my primary care provider for tests. Because of the location of the pain, the chiropractor thought I might be having a gallbladder attack, but the results from a...

Loncastuximab Tesirine May Improve Outcomes in High-Risk Follicular Lymphoma, Marginal Zone Lymphoma

The antibody loncastuximab tesirine may offer a benefit in patients with high-risk follicular lymphoma and marginal zone lymphoma, according to the findings of two clinical trials presented by Alderuccio et al and Lossos et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Issues in Oncology

The Lindy Effect and Open Cancer Surgery

The Lindy effect (also known as Lindy’s Law) is a theorized phenomenon by which the future life expectancy of some nonperishable thing, such as a technology or an idea, is proportional to its current age. Thus, the Lindy effect proposes the longer a period something has survived to exist or be used ...

Advertisement

Rilzabrutinib Found Safe and Effective for Refractory Immune Thrombocytopenia

David J. Kuter, MD, DPhil The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements with other available ITP treatments, according to the results of a...

ASCO Post X Feed
Social Media Hub by Everwall